Synta Pharmaceuticals (SNTA +6.5%) has demonstrated "proof of principle" for its Hsp90-Inhibitor Drug Conjugate (HDC) platform in several pre-clinical cancer models.
The platform caused the complete or near complete regression of tumors in non-small cell lung cancer, small-cell lung cancer, breast cancer, pancreatic cancer, colon cancer, and skin cancer.
The models tested are "generally resistant or show limited response to treatment with the unconjugated chemotherapies," says Synta.
Hsp90 (heat shock protein 90) helps other proteins to fold properly, stabilizes them against heat stress, and aids in protein degradation. Hsp90 also stabilizes a number of proteins required for tumor growth, which is why Hsp90 inhibitors are investigated as cancer therapies (Wikipedia).
"HDCs are small-molecule drugs consisting of an Hsp90 inhibitor joined to an anti-cancer agent," Synta explains. (PR)